ANTX (AN2 Therapeutics) Float Percentage Of Total Shares Outstanding : 62.42% (As of May. 06, 2025)

View and export this data going back to 2022. Start your Free Trial

What is AN2 Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AN2 Therapeutics's float shares is 18.79 Mil. AN2 Therapeutics's total shares outstanding is 30.10 Mil. AN2 Therapeutics's float percentage of total shares outstanding is 62.42%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AN2 Therapeutics's Insider Ownership is 3.14%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AN2 Therapeutics's Institutional Ownership is 48.35%.

AN2 Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

AN2 Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	18.79	/	30.10
	=	62.42%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AN2 Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AN2 Therapeutics Inc (NAS:ANTX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

1800 El Camino Real, Suite D, Menlo Park, CA, USA, 94027

Website

https://www.an2therapeutics.com

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

Executives

Joshua M Eizen	officer: See Remarks	3023 MONTBRETIA WAY, SAN RAMON CA 94582
Lucy Day	officer: Chief Financial Officer	2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Sanjay Chanda	officer: Chief Development Officer	C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Robin Shane Readnour	director	3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215
Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
Eric Easom	director, officer: Chief Executive Officer	171 FOREST LN., MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Adjuvant Global Health Technology Fund De, L.p.	10 percent owner	C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Kabeer Aziz	director	376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211
Kevin Michael Krause	officer: Chief Strategy Officer	369 27TH STREET, SAN FRANCISCO CA 94131
Margaret M Fitzpatrick	director	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Melvin K Spigelman	director	THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Ra Capital Nexus Fund Ii, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Adjuvant Global Health Technology Fund, L.p.	10 percent owner	C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Michael Adrian Nazak	officer: Chief Accounting Officer	5941 OPTICAL COURT, SAN JOSE CA 95138